Is the domestically produced sotorasiib targeted drug already on the market?

Currently, the targeted drug Sotorasib (Sotorasib) has not been officially approved for marketing in my country, so domestic patients cannot purchase it directly through hospitals or pharmacies for the time being. Sotoracib is a targeted drug targeting the KRAS G12C mutation. It is mainly used to treat patients with mutation-positive non-small cell lung cancer (NSCLC). Since KRAS mutations have long been regarded as "undruggable" targets, the emergence of sotorasiib marks an important breakthrough in this field and also brings new treatment hope to some advanced patients.

Although it has not yet been marketed in China, sotorasibu has been approved in many countries and regions. In order to obtain this drug, many domestic patients will choose to purchase it through overseas channels. Currently, there are two options: original drugs and generic drugs on the market. Original drugs are mainly from Europe or Hong Kong, China, and are relatively expensive. A box usually costs tens of thousands of yuan, which is a considerable burden for ordinary families.

In comparison, the prices of foreign generic drugs are obviously more affordable, especially the generic versions from Laos. At present, the price of sotorasibu generic drugs produced by Lao Lucius and Lao Daxiong companies has been significantly reduced. A box of 120mg*56 tablets only costs more than 1,000 yuan. The price is more affordable than the original drug, and it also provides a realistic choice for many patients with limited financial conditions but urgent need for treatment. Importantly, generic drugs contain the same active ingredients as the brand-name drugs and have a similar basis for efficacy.

In general, although sotoracib has not yet been officially launched in my country, patients still have ways to obtain the drug through overseas channels. When choosing, you should weigh multiple factors such as price, efficacy, and safety, and try to conduct treatment under the guidance of a professional doctor. At the same time, patients are advised to pay close attention to the domestic approval status of this drug. Once it is officially launched, the formality and convenience of medication will be greatly improved.

Reference materials:https://www.lumakras.com/